Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04313140
Other study ID # 2019-A02531-56
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date February 22, 2021
Est. completion date June 2026

Study information

Verified date February 2023
Source Poitiers University Hospital
Contact Rémy GUILLEVIN, Pr
Phone 05.49.44.45.42
Email remy.guillevin@chu-poitiers.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Glioma is a tumor of the central nervous system. These lesions are sorted with the WHO ranking regarding the tumoral oncotype. The tumoral MRI assessment is the first step before any medical decision. Currently, only anatomical biopsy can give the tumor grade definition and help to define the most adapted treatment.


Recruitment information / eligibility

Status Recruiting
Enrollment 500
Est. completion date June 2026
Est. primary completion date June 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Age= 18 years, - Patient with suspected glioma with prior imaging - Subject free, with legal protection guardianship or curatorship; - Enrollment in the French Social Security system; - Informed consent signed by the patient Exclusion Criteria: - Any contraindication to an MRI examination - Legal protection, namely minors, persons deprived of their liberty by a judicial or administrative decision, persons residing in a health or social establishment, adults under legal protection and finally patients in emergency situations - Pregnant or lactating women, women of childbearing age who do not have effective contraception

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
Diagnostic test
The intervention occurs only one time (for 2h30), the MRI examination is divided as follow: Cinicial MRI (50 minutes) Research MRI (Phosphorus Spectroscopy, Sodium Imaging)

Locations

Country Name City State
France CHU De Poitiers Poitiers

Sponsors (1)

Lead Sponsor Collaborator
Poitiers University Hospital

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Validation of the virtual biopsy in the context of gliomas through the use of statistical learning algorithms (artificial intelligence) compared to the biopsy. Evaluate the diagnostic capabilities of artificial intelligence algorithms for virtual biopsy based on sensitivity and specificity The MRI examination (for 2 hours 30 minutes)
See also
  Status Clinical Trial Phase
Completed NCT01694108 - Bacille Calmette Guérin Immunisation at Birth and Childhood Morbidity in Danish Children. Phase 4
Not yet recruiting NCT04584424 - Prognostic Factors and Outcomes of COVID-19 Cases in Ethiopia